Clinical Trial Update: To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial is evaluating the safety and tolerability of Study Drug as third-line and beyond therapy for recurrent or metastatic gastric cancer. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Snippet

Sponsor: Onconic Therapeutics Inc. | Conditions: Gastric Cancer (GC) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING